Teva Pharmaceuticals, Inc.
1090 Horsham Road
P.O. Box 1090
About Teva Pharmaceuticals, Inc.
TEVA Pharmaceuticals USA is the nation’s leading generic manufacturer, marketing the broadest product line in the U.S. with over 300 products. The company leads the industry in the number of new and total retail prescriptions in the U.S. Teva Pharmaceuticals USA employs approximately 1,200 people.
We believe that our quality people and the quality products that we market enhance the quality of life of patients and consumers throughout the world. Our achievements are possible due to the diligent efforts and complete dedication of these employees and our employees worldwide.
Part of what makes us successful is that as a company, we constantly analyze where we are today and where we need to be tomorrow. Teva USA's management philosophy is to develop leaders and their associates so that they may achieve professional and career success in the pharmaceutical business.
It is in this spirit that we provide our employees with many training and development opportunities necessary to cultivate and improve their skills, enhancing their career potential and growth. Teva USA views continuing education and development as the means to acquire the tools and techniques necessary to keep its employees and the organization in the forefront of leadership and good business practice.
Teva USA's future as the leader in the generic pharmaceutical industry hinges on both our individual and collective abilities. For these reasons, we rely on our diversity, creative solutions, teamwork and commitment to quality and customer service, which have built a tradition of customer satisfaction, value and profitability.
At Teva Pharmaceuticals USA, in addition to hard work, we also believe in having fun. We reinforce this belief through the events and activities that we sponsor. Company activities include an Easter Egg Hunt, a well-attended company picnic, and an annual Halloween pumpkin-carving contest. We also have an Activities Committee that organizes trips to local sporting events, short day trips, and theatre events. For the sports-minded, we have clubs to join such as running clubs and ski clubs. There's at least one activity or club to suit each and every employee!
As an organization, Teva is active in the community, involved in everything from sponsoring local theatre groups, sports teams and school programs, to donating medicines for humanitarian relief work around the globe.
Teva USA has an individual spirit of giving. Throughout the year employees participate in a variety of community enrichment drives. For example, the American Red Cross is welcomed here for organized Blood Drives. Employees also make contributions to various on-site programs such as food and clothing drives and children's gift-giving programs.
72 articles with Teva Pharmaceuticals, Inc.
Revenues of $4.3 billion
Teva has initiated a search to identify its next CFO. Mr. McClellan is expected to remain in his role through the announcement of third quarter results to assist with a smooth transition.
Bausch Health Companies Inc. along with its wholly owned subsidiary, Salix Pharmaceuticals, one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, have agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. regarding APRISO® extended-release capsules 0.375g.
IONTAS Limited announced an agreement with Teva Pharmaceuticals to apply its technologies and know-how to the optimisation of human antibodies for use as biotherapeutics.
Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
The First Digital Maintenance Asthma Inhaler Therapy with Integrated Sensors Joins Teva’s Digital Rescue Inhaler Therapy to Provide Patients with Technology to Track Treatment Use
Focused primarily on biologics, a core R&D platform on which the company continues to build for future growth, the R&D campus further augments the company’s significant U.S. presence.
Teva to Present New Data on AJOVY® (fremanezumab-vfrm) Injection at the American Headache Society’s 61st Annual Scientific Meeting
Three late breakers, one oral presentation and 27 posters showcase AJOVY as a preventive treatment for migraine
Teva to Host Conference Call to Discuss Second Quarter 2019 Financial Results at 8 a.m. ET on August 7, 2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its second quarter 2019 financial results on Wednesday, August 7, 2019 at 7:00 a.m. ET.
FLAMMA acquires Teva’s Philadelphia cGMP facility marking entry into the US marketplace with labs & pilot plant
Chignolo D’Isola, Bergamo, Italy – July 1, 2019 – Flamma SpA, a preeminent Contract Development and Manufacturing Organization that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients for the pharmaceutical industry, is proud to announce that the company has acquired the Teva’s Chemical Synthesis Center in Malvern, PA in the Philadelphia area.
Indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics
Just Biotherapeutics and Teva Enter an Agreement for the Design and Development of a High Productivity (HP) Biomanufacturing Process
Just Biotherapeutics, Inc. (Just), an integrated design company focused on technologies for accelerating the development and manufacture of biotherapeutics, announced today that they have entered into an agreement with Teva for the design and development of a high productivity (HP) biomanufacturing process.
Company Statement: Teva Reaches Agreement with State of Oklahoma to Resolve State’s Claims Against the Company
Teva Pharmaceuticals USA and related affiliates of Teva Pharmaceutical Industries Ltd., and the state of Oklahoma, have entered into an agreement for a one-time payment of $85 million to the state.
A new poll shows nearly two-thirds of people blame the pharmaceutical companies for the opioid crisis.
A pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the study’s primary endpoint of mean change from baseline in the weekly average number of cluster headache attacks during the 4-week treatment period is unlikely to be met.
Teva Announces Launch of a Generic Version of AndroGel® (testosterone gel) 1.62% CIII in the United States
Currently, one in eight generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
TEVA Pharmaceuticals USA Issues Statement on a Statement by U.S. Department of Health and Human Services Secretary Kathleen Sebelius
TEVA Pharmaceuticals USA Release: Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold